NASDAQ:PRQRProQR Therapeutics Competitors & Alternatives

ProQR Therapeutics (NASDAQ:PRQR) and Nabriva Therapeutics (NASDAQ:NBRV) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their risk, valuation, dividends, institutional ownership, analyst recommendations, earnings and profitability.

Valuation & Earnings

This table compares ProQR Therapeutics and Nabriva Therapeutics' gross revenue, earnings per share (EPS) and valuation.

ProQR Therapeutics has higher earnings, but lower revenue than Nabriva Therapeutics. ProQR Therapeutics is trading at a lower price-to-earnings ratio than Nabriva Therapeutics, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a breakdown of recent ratings and target prices for ProQR Therapeutics and Nabriva Therapeutics, as provided by MarketBeat.

ProQR Therapeutics presently has a consensus target price of $30.6667, indicating a potential upside of 514.56%. Nabriva Therapeutics has a consensus target price of $3.75, indicating a potential upside of 444.27%. Given ProQR Therapeutics' stronger consensus rating and higher probable upside, research analysts clearly believe ProQR Therapeutics is more favorable than Nabriva Therapeutics.

Volatility & Risk

ProQR Therapeutics has a beta of 0.52, meaning that its share price is 48% less volatile than the S&P 500. Comparatively, Nabriva Therapeutics has a beta of 2.39, meaning that its share price is 139% more volatile than the S&P 500.

Insider & Institutional Ownership

59.0% of ProQR Therapeutics shares are owned by institutional investors. Comparatively, 1.6% of Nabriva Therapeutics shares are owned by institutional investors. 2.8% of Nabriva Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Profitability

This table compares ProQR Therapeutics and Nabriva Therapeutics' net margins, return on equity and return on assets.

Summary

ProQR Therapeutics beats Nabriva Therapeutics on 8 of the 13 factors compared between the two stocks.

ProQR Therapeutics (NASDAQ:PRQR) and Amphastar Pharmaceuticals (NASDAQ:AMPH) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their valuation, risk, dividends, analyst recommendations, profitability, institutional ownership and earnings.

Valuation & Earnings

This table compares ProQR Therapeutics and Amphastar Pharmaceuticals' gross revenue, earnings per share (EPS) and valuation.

Amphastar Pharmaceuticals has higher revenue and earnings than ProQR Therapeutics. ProQR Therapeutics is trading at a lower price-to-earnings ratio than Amphastar Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a breakdown of recent ratings and price targets for ProQR Therapeutics and Amphastar Pharmaceuticals, as provided by MarketBeat.com.

ProQR Therapeutics presently has a consensus price target of $30.6667, suggesting a potential upside of 514.56%. Amphastar Pharmaceuticals has a consensus price target of $22.00, suggesting a potential upside of 8.16%. Given ProQR Therapeutics' stronger consensus rating and higher possible upside, research analysts clearly believe ProQR Therapeutics is more favorable than Amphastar Pharmaceuticals.

Risk and Volatility

ProQR Therapeutics has a beta of 0.52, indicating that its stock price is 48% less volatile than the S&P 500. Comparatively, Amphastar Pharmaceuticals has a beta of 1.19, indicating that its stock price is 19% more volatile than the S&P 500.

Insider and Institutional Ownership

59.0% of ProQR Therapeutics shares are owned by institutional investors. Comparatively, 51.8% of Amphastar Pharmaceuticals shares are owned by institutional investors. 29.8% of Amphastar Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Profitability

This table compares ProQR Therapeutics and Amphastar Pharmaceuticals' net margins, return on equity and return on assets.

Summary

Amphastar Pharmaceuticals beats ProQR Therapeutics on 9 of the 13 factors compared between the two stocks.

ProQR Therapeutics (NASDAQ:PRQR) and Arcturus Therapeutics (NASDAQ:ARCT) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their valuation, risk, dividends, analyst recommendations, profitability, institutional ownership and earnings.

Valuation & Earnings

This table compares ProQR Therapeutics and Arcturus Therapeutics' gross revenue, earnings per share (EPS) and valuation.

Arcturus Therapeutics has higher revenue and earnings than ProQR Therapeutics. Arcturus Therapeutics is trading at a lower price-to-earnings ratio than ProQR Therapeutics, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a breakdown of recent ratings and price targets for ProQR Therapeutics and Arcturus Therapeutics, as provided by MarketBeat.com.

ProQR Therapeutics presently has a consensus price target of $30.6667, suggesting a potential upside of 514.56%. Arcturus Therapeutics has a consensus price target of $37.1429, suggesting a potential downside of 20.79%. Given ProQR Therapeutics' stronger consensus rating and higher possible upside, research analysts clearly believe ProQR Therapeutics is more favorable than Arcturus Therapeutics.

Risk and Volatility

ProQR Therapeutics has a beta of 0.52, indicating that its stock price is 48% less volatile than the S&P 500. Comparatively, Arcturus Therapeutics has a beta of 3.16, indicating that its stock price is 216% more volatile than the S&P 500.

Insider and Institutional Ownership

59.0% of ProQR Therapeutics shares are owned by institutional investors. Comparatively, 23.8% of Arcturus Therapeutics shares are owned by institutional investors. 19.2% of Arcturus Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Profitability

This table compares ProQR Therapeutics and Arcturus Therapeutics' net margins, return on equity and return on assets.

Summary

ProQR Therapeutics beats Arcturus Therapeutics on 7 of the 13 factors compared between the two stocks.

ProQR Therapeutics (NASDAQ:PRQR) and Rhythm Pharmaceuticals (NASDAQ:RYTM) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their valuation, risk, dividends, analyst recommendations, profitability, institutional ownership and earnings.

Valuation & Earnings

This table compares ProQR Therapeutics and Rhythm Pharmaceuticals' gross revenue, earnings per share (EPS) and valuation.

Rhythm Pharmaceuticals is trading at a lower price-to-earnings ratio than ProQR Therapeutics, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a breakdown of recent ratings and price targets for ProQR Therapeutics and Rhythm Pharmaceuticals, as provided by MarketBeat.com.

ProQR Therapeutics presently has a consensus price target of $30.6667, suggesting a potential upside of 514.56%. Rhythm Pharmaceuticals has a consensus price target of $34.1667, suggesting a potential upside of 62.62%. Given ProQR Therapeutics' stronger consensus rating and higher possible upside, research analysts clearly believe ProQR Therapeutics is more favorable than Rhythm Pharmaceuticals.

Risk and Volatility

ProQR Therapeutics has a beta of 0.52, indicating that its stock price is 48% less volatile than the S&P 500. Comparatively, Rhythm Pharmaceuticals has a beta of 0.96, indicating that its stock price is 4% less volatile than the S&P 500.

Insider and Institutional Ownership

59.0% of ProQR Therapeutics shares are owned by institutional investors. Comparatively, 92.0% of Rhythm Pharmaceuticals shares are owned by institutional investors. 9.5% of Rhythm Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Profitability

This table compares ProQR Therapeutics and Rhythm Pharmaceuticals' net margins, return on equity and return on assets.

Summary

ProQR Therapeutics beats Rhythm Pharmaceuticals on 6 of the 11 factors compared between the two stocks.

ProQR Therapeutics (NASDAQ:PRQR) and VBI Vaccines (NASDAQ:VBIV) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their valuation, risk, dividends, analyst recommendations, profitability, institutional ownership and earnings.

Analyst Ratings

This is a breakdown of recent ratings and price targets for ProQR Therapeutics and VBI Vaccines, as provided by MarketBeat.com.

ProQR Therapeutics presently has a consensus price target of $30.6667, suggesting a potential upside of 514.56%. VBI Vaccines has a consensus price target of $4.75, suggesting a potential upside of 21.17%. Given ProQR Therapeutics' higher possible upside, research analysts clearly believe ProQR Therapeutics is more favorable than VBI Vaccines.

Valuation & Earnings

This table compares ProQR Therapeutics and VBI Vaccines' gross revenue, earnings per share (EPS) and valuation.

VBI Vaccines has higher revenue and earnings than ProQR Therapeutics. VBI Vaccines is trading at a lower price-to-earnings ratio than ProQR Therapeutics, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares ProQR Therapeutics and VBI Vaccines' net margins, return on equity and return on assets.

Risk and Volatility

ProQR Therapeutics has a beta of 0.52, indicating that its stock price is 48% less volatile than the S&P 500. Comparatively, VBI Vaccines has a beta of 1.74, indicating that its stock price is 74% more volatile than the S&P 500.

Insider and Institutional Ownership

59.0% of ProQR Therapeutics shares are owned by institutional investors. Comparatively, 33.9% of VBI Vaccines shares are owned by institutional investors. 10.5% of VBI Vaccines shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Summary

VBI Vaccines beats ProQR Therapeutics on 7 of the 11 factors compared between the two stocks.

Gossamer Bio (NASDAQ:GOSS) and ProQR Therapeutics (NASDAQ:PRQR) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, dividends, risk, earnings, institutional ownership, analyst recommendations and valuation.

Analyst Ratings

This is a summary of current ratings and recommmendations for Gossamer Bio and ProQR Therapeutics, as reported by MarketBeat.

Gossamer Bio presently has a consensus price target of $29.50, suggesting a potential upside of 125.36%. ProQR Therapeutics has a consensus price target of $30.6667, suggesting a potential upside of 514.56%. Given ProQR Therapeutics' higher possible upside, analysts plainly believe ProQR Therapeutics is more favorable than Gossamer Bio.

Valuation and Earnings

This table compares Gossamer Bio and ProQR Therapeutics' gross revenue, earnings per share and valuation.

Gossamer Bio is trading at a lower price-to-earnings ratio than ProQR Therapeutics, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Gossamer Bio and ProQR Therapeutics' net margins, return on equity and return on assets.

Volatility & Risk

Gossamer Bio has a beta of 1.15, suggesting that its share price is 15% more volatile than the S&P 500. Comparatively, ProQR Therapeutics has a beta of 0.52, suggesting that its share price is 48% less volatile than the S&P 500.

Institutional and Insider Ownership

58.1% of Gossamer Bio shares are owned by institutional investors. Comparatively, 59.0% of ProQR Therapeutics shares are owned by institutional investors. 23.3% of Gossamer Bio shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.